Drug
5'-oleoyl cytarabine clinical trials
Also written CP-4055 and Elacytarabine.
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Clavis Pharma (9)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Studies
Open first, then newest update. How each study uses 5'-oleoyl cytarabine is read from its arms, and is right about nine times in ten.
Testing it · 9
- Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)CompletedPhase 3Clavis PharmaNCT01147939Written as Elacytarabine
- A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid LeukaemiaCompletedPhase 2Clavis PharmaNCT01035502Written as Elacytarabine plus idarubicin
- The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)CompletedPhase 1Clavis PharmaNCT01258816Written as Elacytarabine for infusion
- A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic MalignanciesCompletedPhase 1/2Clavis PharmaNCT00405743Written as CP-4055
- A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian CancerCompletedPhase 1/2Clavis PharmaNCT00831636Written as CP-4055
- Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant MelanomaCompletedPhase 2Clavis PharmaNCT00498836Written as CP-4055
- Elacytarabine Mass Balance Study in Healthy VolunteersCompletedPhase 1Clavis PharmaNCT01783964Written as [14C]-Elacytarabine
- A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal CancerCompletedPhase 2Clavis PharmaNCT00498407Written as CP-4055
- Clinical Study of Previously Untreated Patients With Malignant MelanomaCompletedPhase 2Clavis PharmaNCT00232726Written as CP-4055 (ELACYT)